Navigation Links
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Date:11/2/2010

cluding, without limitation: our dependence on the successful commercialization of OFIRMEV; the potential that we will require substantial additional funding in order to effectively commercialize OFIRMEV, and the risk that we may not be able to raise sufficient capital when needed, or at all; the risk that delays in commercially launching OFIRMEV would enable competitors to further entrench their existing products or develop and bring new products to market before OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; our ability to comply with the terms of our loan agreement, and draw down additional amounts under our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the impact of healthcare reform legislation; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence™ and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.  Contacts:INVESTORS

MEDIACadence Pharmaceuticals, Inc.

WCGWilliam R. LaRue, SVP and Chief Financial Officer

Hayley Soffer858-436-1400

212-301-7176blarue@cadencepharm.com

hsoffer@w
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
(Date:4/17/2015)... 17, 2015  Guggenheim Securities, the investment banking and ... hiring of William Tanner as a Managing ... Tanner will start work at Guggenheim in May 2015 ... office. "Bill brings a wealth of biotech ... experienced and highly acclaimed healthcare team," said Matthew ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/17/2015)... Madison, WI (PRWEB) April 17, 2015 ... provide sales and marketing support for the powerful ... at the Chemical Genomics Center at the Lankenau ... LCGC’s mission is to measurably improve successful ... to HTS, by offering rare, drug-like libraries available ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... Genstruct Inc., a,biotechnology company translating the complexity of ... that its president and,CEO, Dr. Keith O. Elliston, ... Trial Summit in Arlington, Va., September 17-18. ... focused on,"Enhancing Development and Commercial Value Added in ...
... Over 20 Targanta-Related Posters and Presentations Accepted ... Targanta Therapeutics,Corporation today announced that 23 ... and its antibiotic drug discovery,platform at the ... and Chemotherapy (ICAAC), taking place in Chicago,September ...
... NORTH BRUNSWICK, New Jersey, September 12, Rosetta ... in,the development of microRNA-based diagnostics and therapeutics, ... Bentwich will present AACR,s,upcoming Molecular Diagnostics in ... focus on Rosetta Genomics,unique microRNA-based technologies and ...
Cached Biology Technology:Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 3Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 4Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 5Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 6Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 7Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Washington, DC, June 13, 2008 Mary Tyler Moore, ... husband, S. Robert Levine, M.D., presented the sixth annual ... Florida scientists at JDRF,s annual conference today in Washington, ... are Mark Atkinson, Ph.D., director of the JDRF Gene ...
... Julia Zeitlinger, Ph.D., Assistant Investigator, has been named a ... Trusts. The honor carries an award of $240,000 over ... Pew Scholars are selected on the basis of performance ... as contributors in science relevant to human health. The ...
... --- iZumi Bio, Inc. and The J. David Gladstone ... a major research collaboration and licensing agreement to focus ... iPS cells are "reprogrammed" adult cells that have ... stem (ES) cells, yet do not raise the same ...
Cached Biology News:Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2Julia Zeitlinger named Pew Scholar 2
... Experion HighSens reagents and supplies, ... and supplies sufficient to perform high-sensitivity ... chips on the Experion automated electrophoresis ... gel, 20 microliters RNA HighSens stain, ...
...
... BIP-NC H-IPMIK-OH Lyophilized solid. ... LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A ... V5 (Cat. No. 196810) that serves as ... apoptosis (~200 μM). Purity: ≥97% by ...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: